8-Hydroxyquinoline-modified ruthenium(<scp>ii</scp>) polypyridyl complexes for JMJD inhibition and photodynamic antitumor therapy

Ma, Xiu-Rong; Lu, Junjian; Yang, Peixin; Zhang, Zheng; Huang, Bo; Li, Rong‐Tao; Ye, Rui-Rong

doi:10.1039/d2dt01765b

Cited by 12 publications

(4 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ROS generation pathways: A crucial mechanism in the photodynamic treatment (PDT) process, which is mediated by Ru(II) complexes, is the formation of reactive oxygen species (ROS) [77][78][79][80]. These complexes can go through photochemical processes upon light activation, producing a variety of ROS species.…”

Section: Design Strategies For Ru(ii) Complexes In Pdtmentioning

confidence: 99%

A Comprehensive Review for Ruthenium(II) Complexes in Photodynamic Therapy

Mukherjee

2023

ajc

View full text Add to dashboard Cite

Photodynamic therapy (PDT) has emerged as a promising therapeutic approach for the treatment of various diseases, including cancer. In recent years, ruthenium(II) complexes have garnered significant interests as photsensitizers in PDT due to their unique photophysical properties and versatile coordination chemistry. The current developments in the use of Ru(II) complexes as photosensitizers in PDT are thoroughly examined in this review article. The design techniques used to increase their photodynamic effectiveness, increase selectivity and reduce off-target impacts are discussed. The formation of reactive oxygen species (ROS) and the ways in which they influence biological processes are also being explored. Additionally, the Ru(II) complexes with dual functioning, targeting abilities and uses in various disease models are highlighted. Prospects and challenges in this area such as water solubility, biocompatibility and translational issues are discussed. The goal of this review article is to provide a thorough overview of the potential of Ru(II) complexes in PDT and to inspire additional investigation in this fascinating field.

show abstract

Section: Design Strategies For Ru(ii) Complexes In Pdtmentioning

confidence: 99%

A Comprehensive Review for Ruthenium(II) Complexes in Photodynamic Therapy

Mukherjee

2023

ajc

View full text Add to dashboard Cite

show abstract

“…25,26 Due to their excellent photophysical properties and singlet oxygen yield, ruthenium(II) complexes find use as photosensitizers for photodynamic therapy (PDT) and are expected to be a new generation of anticancer drugs. [27][28][29] Photodynamic therapy is an emerging tumor therapy that kills tumor cells by activating reactive oxygen species (ROS) produced by photosensitizers, on account of its high therapeutic efficacy and low toxicity side effects, and has gradually become a promising anticancer treatment. 30 But on the other hand, conventional photosensitizers are currently limited by their low water solubility, so improving the water solubility of photosensitizers could promote the application of PDT.…”

Section: Introductionmentioning

confidence: 99%

Mitochondria-targeted ruthenium(ii) complexes for photodynamic therapy and GSH detection in living cells

Zhang,

Chen,

et al. 2024

Dalton Trans.

View full text Add to dashboard Cite

show abstract

“…Besides the mentioned inhibitors above, metal complexes have been applied to reduce side effects and improve the selectivity of molecules to MMPs. Along with the multiple metal complexes that have anti-tumor ability targeting DNA/RNA or mitochondria and anti-Aβ aggregation ability to reduce the risk of onset and/or progression of cancers and AD [ 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 ], various metal complexes (e.g., Pt-, Ru-, Fe-, Cu-, Au-, Ni-, Zn, Sn-complexes) could be applied as regulators for both expression and enzymatic activity of MMPs. Those metal complexes could be applied as cancer and AD treatments later.…”

Section: Introductionmentioning

confidence: 99%

Metal Complexes as Promising Matrix Metalloproteinases Regulators

Nguyen

Kim

Lee

2023

IJMS

View full text Add to dashboard Cite

Nowadays, cancers and dementia, such as Alzheimer’s disease, are the most fatal causes of death. Many studies tried to understand the pathogenesis of those diseases clearly and develop a promising way to treat the diseases. Matrix metalloproteinases (MMPs) have been reported to be involved in the pathology of cancers and AD through tumor cell movement and amyloid degradation. Therefore, control of the levels and actions of MMPs, especially MMP-2 and MMP-9, is necessary to care for and/or cure cancer and AD. Various molecules have been examined for their potential application as regulators of MMPs expression and activity. Among the molecules, multiple metal complexes have shown advantages, including simple synthesis, less toxicity and specificity toward MMPs in cancer cells or in the brain. In this review, we summarize the recent studies and knowledge of metal complexes (e.g., Pt-, Ru-, Au-, Fe-, Cu-, Ni-, Zn-, and Sn-complexes) targeting MMPs and their potentials for treating and/or caring the most fatal human diseases, cancers and AD.

show abstract

8-Hydroxyquinoline-modified ruthenium(ii) polypyridyl complexes for JMJD inhibition and photodynamic antitumor therapy

Abstract: As an ideal scaffold for metal ion chelation, 8-hydroxyquinoline (8HQ) can chelate different metal ions, such as Fe2+, Cu2+, Zn2+, etc. Here, by integrating 8HQ with ruthenium(II) polypyridyl moiety, two...

Cited by 12 publications

References 60 publications

A Comprehensive Review for Ruthenium(II) Complexes in Photodynamic Therapy

A Comprehensive Review for Ruthenium(II) Complexes in Photodynamic Therapy

Mitochondria-targeted ruthenium(ii) complexes for photodynamic therapy and GSH detection in living cells

Metal Complexes as Promising Matrix Metalloproteinases Regulators

Contact Info

Product

Resources

About